

14
13. A peptide comprising or consisting of the sequence YMVH or MVHW or VHWK and having at least 70% homology with part or all of the sequence

AEPHRWSSYIMVHWK.

15
14. A mixture of the peptide of claim ¹³12 or claim ¹⁴13 with another peptide having at least 4 amino acid residues and having at least 70% homology with the β -amyloid precursor sequence

DAEFRHDSGYEVHHQK.

16
15. A probe consisting of the peptide of claim ¹³12 or claim ¹⁴13, labelled with a signal moiety, or immobilised on a support.

17
16. A probe consisting of the peptide of claim ¹⁵15, labelled with a signal moiety, or immobilised on a support.

18
17. A compound which competes with the peptide of claim ¹³12 or claim ¹⁴13 for binding to a receptor therefor and which thereby inhibits the biological activity of the said peptide.

19
18. A compound as claimed in claim ¹⁸17, wherein the biological activity is modulating a calcium-channel-opening activity.

20
19. A compound as claimed in claim ¹⁸17, which is capable of crossing the blood-brain barrier.

21
20. An antibody to the peptide of claim ¹³12 or claim 13.

22
21. An antibody as claimed in claim ²¹20 which is of the IgG class.

23
22. An antibody fragment or chimeric or humanised antibody comprising variable regions of the antibody of claim ²¹20.

~~23. A method of treating a patient suffering from a disorder of the central nervous system or stroke or cancer, which method comprises administering to the patient a compound according to claim 17.~~

~~24. A method of treating a patient suffering from a disorder of the central nervous system or stroke or cancer, which method comprises administering to the patient an antibody according to claim 20.~~

~~25. A method of controlling cytoplasmic calcium ion concentration in vivo, which method comprises administering a compound according to claim 17.~~

~~26. A method of controlling cytoplasmic calcium ion concentration in vivo, which method comprises administering an antibody according to claim 20.~~

~~27. A peptide as claimed in claim 12 or claim 13, which peptide contains no more than about 14 amino acid residues.~~

~~28. A peptide as claimed in claim 12 or claim 13, which peptide does not form part of a larger protein having homology with the AChE molecule.~~

~~29. A peptide as claimed in claim 12 or claim 13, which peptide is a fragment of the AChE molecule.~~

~~30. A peptide as claimed in claim 12 or claim 13, which peptide has been chemically synthesised. --~~